MET appears to have been first described in the literature in 1981.[8] It was only briefly mentioned inAlexander Shulgin's 1997 bookTiHKAL (Tryptamines I Have Known and Loved).[1] The drug was encountered as a noveldesigner drug inEurope in 2014.[9]
MET appears to have first been described in the literature by 1981.[8] It was specifically mentioned in Michael Valentine Smith'sPsychedelic Chemistry.[8] Subsequently, MET was briefly described inAlexander Shulgin'sTiHKAL (Tryptamines I Have Known and Loved) in 1997.[1] MET was encountered as a noveldesigner drug inEurope in 2014.[9]
^abcdefghijklmShulgin AT,Shulgin A (1997).TiHKAL: The Continuation (1st ed.). Berkeley, CA: Transform Press.ISBN978-0-9630096-9-2.OCLC38503252. Retrieved30 January 2025.MET; positive, psychedelic; 80–100 mg [...] Lying midway between DMT and DIPT is the ethyl compound, N-ethyl-N-methyltryptamine, or MET. It can be made by adding ethyl acetate to a reaction mixture where the formamide of tryptamine (see under NMT) has been reduced to NMT but there is still a goodly excess of hydride still remaining. The free base, as an oil, shows oral activity in the eighty to one hundred milligram range, so going from a methyl to an ethyl does indeed protect the compound from total enzymatic annihilation when taken orally.
^abcdeMalaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA (December 2020)."Toxicology and Analysis of Psychoactive Tryptamines".Int J Mol Sci.21 (23): 9279.doi:10.3390/ijms21239279.PMC7730282.PMID33291798.N-methyl-N-ethyltryptamine (MET): MET is structurally related to DMT but little scientific information is available on its pharmacology or toxicity in humans. Inhalation of 15 mg freebase MET or 80–100 mg oral freebase MET produce effects [73]. Anecdotal reports describe the most common physical and psychological effects as physical euphoria, tactile enhancement, increased heart rate and blood pressure, muscle cramps, teeth grinding, pupil dilation, hallucinations and cognitive effects [73].
^abcdefgUS 11440879, Kruegel AC, "Methods of treating mood disorders", issued 13 September 2022, assigned to Gilgamesh Pharmaceuticals Inc.
^Schifano F, Orsolini L, Papanti D, Corkery J (2016). "NPS: Medical Consequences Associated with Their Intake".Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. pp. 351–380.doi:10.1007/7854_2016_15.ISBN978-3-319-52442-9.PMID27272067.
^abHalberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior".Behavioral Neurobiology of Psychedelic Drugs. Curr Top Behav Neurosci. Vol. 36. pp. 159–199.doi:10.1007/7854_2016_466.ISBN978-3-662-55878-2.PMC5787039.PMID28224459.The HTR has also been observed in rodents treated with N-methyl-N-ethyltryptamine (MET), N,N-diethyltryptamine (DET), N,N-dipropyltryptamine (DPT), N,N-diisopropyltryptamine (DIPT), and N,N-diallyltryptamine (DALT) (Fantegrossi et al. 2008; Smith et al. 2014; Carbonaro et al. 2015; Halberstadt and Klein, unpublished observations).
